Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study

References

• Albisinni S, Biaou I, Marcelis Q, et al. New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives. BMC Urol. 2016;16:58.
   PubMed Web of Science ®Google Scholar
• Moss MC, Rezan T, Karaman UR, et al. Treatment of concomitant OAB and BPH. Curr Urol Rep. 2017;18:1.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49:651–658.
   PubMed Web of Science ®Google Scholar
• Yeh HC, Liu CC, Lee YC, et al. Associations of the lower urinary tract symptoms with the lifestyle, prostate volume, and metabolic syndrome in the elderly males. Aging Male. 2012;15:166–172.
   PubMed Web of Science ®Google Scholar
• Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001;166:550–552.
   PubMed Web of Science ®Google Scholar
• Knutson T, Edlund C, Fall M, et al. BPH with coexisting overactive bladder dysfunction–an everyday urological dilemma. Neurourol Urodyn. 2001;20:237–247.
   PubMed Web of Science ®Google Scholar
• Salah Azab S, Elsheikh MG. The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS. Aging Male. 2015;18:89–92.
   PubMed Web of Science ®Google Scholar
• Singam P, Hong GE, Ho C, et al. Nocturia in patients with benign prostatic hyperplasia: evaluating the significance of ageing, co-morbid illnesses, lifestyle and medical therapy in treatment outcome in real life practice. Aging Male. 2015;18:112–117.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104:352–360.
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–766.
   PubMed Web of Science ®Google Scholar
• Statistiska Centralbyrån. Statistical database - population by age and sex 2016. [cited 2017 Feb 21]. Available from: http://www.statistikdatabasen.scb.se.
   Google Scholar
• Swedish Medical Products Agency. Behandling av urinträngningar och trängningsinkontinens - överaktiv blåsa - ny rekommendation. Läkemedelsverket. 2011;22:12–21. Available from: https://lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/Ny%20rekommendation%20%E2%80%93%20%20behandling%20av%20urintr%C3%A4ngningar%20och%20tr%C3%A4ngningsinkontinens%20%E2%80%93%20%C3%B6veraktiv%20bl%C3%A5sa%20%5B1%5D.pdf [last accessed Feb 21, 2017].
   Google Scholar
• Swedish Medical Products Agency. Läkemedelsverket informerar - godkända läkemedel. January 2013. [cited 2017 Feb 27]. Available from: https://lakemedelsverket.se/upload/foretag/humanlakemedel/godkannandelistor/g01_2013.pdf.
   Google Scholar
• Oelke M, Speakman MJ, Desgrandchamps F, et al. Acute urinary retention rates in the general male population and in adult men with lower urinary tract symptoms participating in pharmacotherapy trials: a literature review. Urology. 2015;86:654–665.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005;174:2273–2275.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Abrams P, Rovner ES, et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006;97:1003–1006.
   PubMed Web of Science ®Google Scholar
• Abrams P, Kaplan S, De Koning Gans HJ, et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175:999–1004.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Dmochowski R, et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006;68:328–332.
   PubMed Web of Science ®Google Scholar
• Kosilov K, Loparev S, Ivanovskaya M, et al. Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with tamsulosin. Aging Male. 2015;18:44–48.
   PubMed Web of Science ®Google Scholar
• Lee KW, Hur KJ, Kim SH, et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Low Urin Tract Symptoms. 2016. [Epub ahead of print]. doi:10.1111/luts.12124
   Web of Science ®Google Scholar
• Matsukawa Y, Takai S, Funahashi Y, et al. Long-term efficacy of a combination therapy with an anticholinergic agent and an alpha1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourol Urodyn. 2017;36:748–754.
   PubMed Web of Science ®Google Scholar
• Yamanishi T, Asakura H, Seki N, Tokunaga S. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: a multicenter, randomized, open-label, controlled trial (DIrecT Study). Int J Urol. 2017;24:525–531.
   PubMed Web of Science ®Google Scholar
• European Association of Urology. Treatment of non-neurogenic male LUTS. 2017. [cited 2017 Feb 18]. Available from: http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts
   Google Scholar
• Blasco P, Valdivia MI, Ona MR, et al. Clinical characteristics, beliefs, and coping strategies among older patients with overactive bladder. Neurourol Urodyn. 2017:36:774–779.
   PubMed Web of Science ®Google Scholar
• Kinsey D, Pretorius S, Glover L, et al. The psychological impact of overactive bladder: a systematic review. J Health Psychol. 2016;21:69–81.
   PubMed Web of Science ®Google Scholar
• McVary KT, Peterson A, Donatucci CF, et al. Use of structural equation modeling to demonstrate the differential impact of storage and voiding lower urinary tract symptoms on symptom bother and quality of life during treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2016;196:824–830.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Eryuzlu LN, Cartwright R, et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol. 2014;65:1211–1217.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kelleher CJ, Evans CJ, et al. A narrative review of patient-reported outcomes in overactive bladder: what is the way of the future? Eur Urol. 2016;70:799–805.
   PubMed Web of Science ®Google Scholar
• Van Kerrebroeck P, Haab F, Angulo JC, et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol. 2013;64:398–407.
   PubMed Web of Science ®Google Scholar
• Obata J, Matsumoto K, Yamanaka H, et al. Who would benefit from solifenacin add-on therapy to tamsulosin for overactive bladder symptoms associated with benign prostatic hyperplasia? Low Urin Tract Symptoms. 2013;5:145–149.
   PubMed Web of Science ®Google Scholar
• Masumori N, Tsukamoto T, Yanase M, et al. The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction. Adv Urol. 2010; Article ID 205251.
   PubMedGoogle Scholar
• van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013;64:1003–1012.
   PubMed Web of Science ®Google Scholar
• Drake MJ, Chapple C, Sokol R, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015;67:262–270.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172:1919–1924.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303–310.
   PubMed Web of Science ®Google Scholar
• Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005;47:376–384.
   PubMed Web of Science ®Google Scholar
• Brostrom S, Hallas J. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol. 2009;65:309–314.
   PubMed Web of Science ®Google Scholar
• Hakimi Z, Johnson M, Nazir J, et al. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data. Curr Med Res Opin. 2015;31:43–50.
   PubMed Web of Science ®Google Scholar
• Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol. 2014;191:1003–1008.
   PubMed Web of Science ®Google Scholar
• Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin. 2002;18:177–184.
   PubMed Web of Science ®Google Scholar
• Landis JR, Kaplan S, Swift S, et al. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol. 2004;171:752–756.
   PubMed Web of Science ®Google Scholar
• Abrams P, Larsson G, Chapple C, et al. Factors involved in the success of antimuscarinic treatment. BJU Int. 1999;83 Suppl 2:42–47.
   PubMed Web of Science ®Google Scholar